dupilumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate to Severe Atopic Hand and Foot Dermatitis
Conditions
Moderate to Severe Atopic Hand and Foot Dermatitis
Trial Timeline
Apr 14, 2021 → Nov 23, 2022
NCT ID
NCT04417894About dupilumab + Placebo
dupilumab + Placebo is a phase 3 stage product being developed by Sanofi for Moderate to Severe Atopic Hand and Foot Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04417894. Target conditions include Moderate to Severe Atopic Hand and Foot Dermatitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07053423 | Approved | Recruiting |
| NCT06687967 | Phase 3 | Active |
| NCT06687980 | Phase 3 | Active |
| NCT06191315 | Phase 3 | Recruiting |
| NCT06101095 | Approved | Active |
| NCT05731128 | Phase 2 | Active |
| NCT05097287 | Approved | Recruiting |
| NCT04988022 | Approved | Completed |
| NCT04417894 | Phase 3 | Completed |
| NCT04442269 | Phase 2 | Completed |
| NCT04512339 | Phase 2 | UNKNOWN |
| NCT04400318 | Approved | Completed |
| NCT04033367 | Approved | Completed |
| NCT03749148 | Phase 2 | Completed |
| NCT03749135 | Phase 2 | Completed |
| NCT03633617 | Phase 3 | Completed |
| NCT03389893 | Approved | Terminated |
| NCT03359356 | Phase 2 | Completed |
| NCT03054428 | Phase 3 | Completed |
| NCT02379052 | Phase 2 | Completed |
Competing Products
20 competing products in Moderate to Severe Atopic Hand and Foot Dermatitis